Načítá se...

Lack of a Significant Drug Interaction between Raltegravir and Tenofovir

Raltegravir is a novel human immunodeficiency virus type 1 (HIV-1) integrase inhibitor with potent in vitro activity (95% inhibitory concentration of 31 nM in 50% human serum). This article reports the results of an open-label, sequential, three-period study of healthy subjects. Period 1 involved ra...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Wenning, Larissa A., Friedman, Evan J., Kost, James T., Breidinger, Sheila A., Stek, Jon E., Lasseter, Kenneth C., Gottesdiener, Keith M., Chen, Joshua, Teppler, Hedy, Wagner, John A., Stone, Julie A., Iwamoto, Marian
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society for Microbiology (ASM) 2008
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2533504/
https://ncbi.nlm.nih.gov/pubmed/18625763
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00005-08
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!